drugset
Drugs / Human amniotic-derived mesenchymal stem cells
last change Jun 2022 re-read 3 minutes ago

Human amniotic-derived mesenchymal stem cells

also known as hAMSCs · human amnion-derived mesenchymal stem cells

Cell therapy

Developed for
calciphylaxis
Investigated by
The First Affiliated Hospital with Nanjing Medical University · Westlake University

Trials 1

today NCT04592640 · Ph 0
201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 0 NCT04592640 Sep 2018 → Sep 2027 expected calciphylaxis, chronic kidney disease The First Affiliated Hospital with Nanjing Medical University Recruiting No outcome recorded

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as Human amniotic-derived mesenchymal stem cells ClinicalTrials.gov intervention name — accepted as the source's own label NCT04592640 ↗
Known as hAMSCs “treatment with human amnion-derived mesenchymal stem cells (hAMSCs) was approved.” PMID 35142858 ↗ Jun 2022
Known as human amnion-derived mesenchymal stem cells “treatment with human amnion-derived mesenchymal stem cells (hAMSCs) was approved.” PMID 35142858 ↗ Jun 2022
Modality Cell therapy “Biological: Human amniotic-derived mesenchymal stem cells” NCT04592640 ↗
Route Intravenous “Intravenous infusion” NCT04592640 ↗